Initial purchase: 7/1/2015 (BAX spinoff)
Cost basis: $36.02
Current Portfolio Status: Other
Dividend Reinvestment: N
Dividends paid quarterly in Jan, Apr, Jul, Oct
Shares held on account at Motif
Baxalta Incorporated, a biopharmaceutical company, develops, manufactures, and markets a portfolio of products primarily for the treatment of hematology and immunology worldwide. It also offers other therapies for the treatments of bleeding disorders, and chronic and acute medical conditions, including hemophilia A, hemophilia B, acquired hemophilia, inhibitor treatments, primary immunodeficiency (PID), and alpha-1 antitrypsin deficiency. The companys principal products include ADVATE, a recombinant factor VIII therapy for the treatment of children and adults with hemophilia A; FEIBA, an inhibitor management therapy; GAMMAGARD LIQUID, a liquid formulation of the antibody-replacement therapy for the treatment of immune deficiencies and certain neurological disorders; and HYQVIA, an immune globulin with a recombinant human hyaluronidase for the treatment of PID in adults. It is also developing products in the areas of hematology, oncology, immunology, and biosimilars. The company has collaboration agreements with National Center for Advancing Translational Sciences, Coherus BioSciences, Inc., Merrimack Pharmaceuticals, Inc., and Momenta Pharmaceuticals, Inc., as well as licensing agreement with CTI BioPharma Corp. Baxalta Incorporated was incorporated in 2014 and is based in Bannockburn, Illinois. Baxalta, Inc. was spun off from Baxter International, Inc. July 1, 2015.
Reason for holding: Pending acquisition by Shire